Clenbuterol, Ko te agonist β2-adrenergic (β2-adrenergic agonist), rite ki te ephedrine (Ephedrine), Kei te maha whakamahia haumanu ki te hamani mate pūkahukahu aukati mau tonu (COPD), Kei te whakamahia hoki te reira rite te bronchodilator ki te atawhai exacerbations whakapeka o te huangō.I te timatanga o te tekau tau atu i 1980, ka kitea e te kamupene o Amerika a Cyanamid he huanga o te whakatairanga i te tipu, te whakapai ake i te reiti mīti hiroki me te whakaiti i te ngako, na reira i whakamahia hei clenbuterol i roto i nga mahi ahuwhenua.Heoi, na ona paanga kino, ka whakakorehia e te Hapori Pakeha te whakamahi i te clenbuterol hei taapiri kai mai i te Hanuere 1, 1988. I aukatihia e te FDA i te tau 1991. I te tau 1997, ka tino rahuitia e te Manatu Ahuwhenua o te Tangata o Haina. te whakamahi o nga homoni beta-adrenergic i roto i te kai me te mahi ahuwhenua kararehe, me te Clenbuterol hydrochloride te tuatahi.
Heoi, kua kitea tata nei te Clenbuterol racemic ki te whakaiti i te tupono o te mate o Parkinson.Hei whakapumau ko wai (e rua ranei) nga ngohe e whakaputa ana i tenei paanga, me ako motuhake te Clenbuterol enantiomer parakore.
I roto i te tuhinga tata nei, ko te roopu rangahau a Elisabeth Egholm Jacobsen o te Tari Matū, Te Whare Wananga o te Whare Wananga o Norwegian o te Putaiao me te Hangarau, i te mahi tahi me Dr. Zhu Wei o Shangke Bio, i whakakoi i te whakahiato o te ketoreductase KRED me te cofactor nicotinamide adenine dinucleoside phosphate (NADPH). ).(R)-1-(4-Amino-3,5-dichlorophenyl)-2-bromoethan-1-ol, ee > 93%;me te (S)-N-(2 i whakahiatohia e te punaha ano ,6-Dichloro-4-(1-hydroxyethyl)phenyl)acetamide, ee >98%.E rua o nga takawaenga i runga ake he kawainga o te inemate clenbuterol.Ko te ketoreductase ES-KRED-228 i whakamahia i roto i tenei rangahau mai i Shangke Biopharmaceutical (Shanghai) Co., Ltd. Ko te hua rangahau "Chemoenzymatic Synthesis of Synthons as Precursors for Enantiopure Clenbuterol and Other -2-Agonists" i whakaputaina i roto i "Catalysts" i runga i Noema 4, 2018.
Wā tuku: Akuhata-26-2022